Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques.

Verma A, Schmidt BA, Elizaldi SR, Nguyen NK, Walter KA, Beck Z, Trinh HV, Dinsarapu AR, Lakshmanappa YS, Rane NN, Matyas GR, Rao M, Shen X, Tomaras GD, LaBranche CC, Reimann KA, Foehl DH, Gach JS, Forthal DN, Kozlowski PA, Amara RR, Iyer SS.

J Virol. 2019 Dec 11. pii: JVI.01737-19. doi: 10.1128/JVI.01737-19. [Epub ahead of print]

2.

Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Gach JS, Mara KJV, LaBranche CC, van Gils MJ, McCoy LE, Klasse PJ, Montefiori DC, Sanders RW, Moore JP, Forthal DN.

J Virol. 2019 Sep 30;93(20). pii: e01188-19. doi: 10.1128/JVI.01188-19. Print 2019 Oct 15.

PMID:
31375582
3.

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.

Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G.

Nat Med. 2018 Jun;24(6):847-856. doi: 10.1038/s41591-018-0025-7. Epub 2018 May 21.

4.

Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.

Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal DN.

PLoS Pathog. 2017 Dec 27;13(12):e1006793. doi: 10.1371/journal.ppat.1006793. eCollection 2017 Dec.

5.

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J.

J Virol. 2018 Jan 2;92(2). pii: e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15.

6.

Recent Insights into the HIV/AIDS Pandemic.

Becerra JC, Bildstein LS, Gach JS.

Microb Cell. 2016 Sep 5;3(9):451-475. doi: 10.15698/mic2016.09.529. Review.

7.

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ.

PLoS One. 2016 Aug 8;11(8):e0160341. doi: 10.1371/journal.pone.0160341. eCollection 2016.

8.

Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Gach JS, Venzon D, Vaccari M, Keele BF, Franchini G, Forthal DN.

J Virol. 2016 Sep 12;90(19):8487-95. doi: 10.1128/JVI.00812-16. Print 2016 Oct 1.

9.

HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.

Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J.

EBioMedicine. 2015 Oct;2(10):1464-77.

10.

Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.

Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12675-80. doi: 10.1073/pnas.1509090112. Epub 2015 Sep 28.

11.

A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.

Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal DN, Felgner PL, Gach JS.

PLoS One. 2015 May 4;10(5):e0125581. doi: 10.1371/journal.pone.0125581. eCollection 2015.

12.

Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM.

Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauernfried S, Furtmüller PG, Forthal DN, Mach L, Obinger C, Kunert R.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt A):1536-44. doi: 10.1016/j.bbapap.2015.02.018. Epub 2015 Mar 5.

13.

Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN.

J Infect Dis. 2015 Jan 1;211(1):45-52. doi: 10.1093/infdis/jiu300. Epub 2014 May 21.

14.

HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.

Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL.

PLoS One. 2014 Jan 15;9(1):e85371. doi: 10.1371/journal.pone.0085371. eCollection 2014.

15.

Anti-p21 autoantibodies detected in colorectal cancer patients: A proof of concept study.

Bishehsari F, Gach JS, Akagi N, Webber MK, Bauer J, Jung BH.

Oncoimmunology. 2014 Nov 14;3(8):e952202. eCollection 2014.

16.

The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN.

PLoS Pathog. 2013;9(11):e1003776. doi: 10.1371/journal.ppat.1003776. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Nov;9(11). doi:10.1371/annotation/31430955-703b-484a-96eb-e180f917d683.

17.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

18.

Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules.

Gach JS, Leaman DP, Zwick MB.

Curr Top Med Chem. 2011 Dec;11(24):2997-3021. Review.

PMID:
22044228
19.

Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA.

J Mol Biol. 2011 Dec 2;414(3):460-76. doi: 10.1016/j.jmb.2011.10.014. Epub 2011 Oct 15.

20.

Synthesis and analysis of the membrane proximal external region epitopes of HIV-1.

Ingale S, Gach JS, Zwick MB, Dawson PE.

J Pept Sci. 2010 Dec;16(12):716-22. doi: 10.1002/psc.1325.

PMID:
21104968
21.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

22.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

23.

4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.

Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F, Decker JM, Heath L, Decker WD, Sinkala M, Kankasa C, Thea D, Mullins J, Kuhn L, Zwick MB, Aldrovandi GM.

PLoS One. 2010 Mar 23;5(3):e9786. doi: 10.1371/journal.pone.0009786.

24.

Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.

Gach JS, Furtmüller PG, Quendler H, Messner P, Wagner R, Katinger H, Kunert R.

J Biol Chem. 2010 Jan 8;285(2):1122-7. doi: 10.1074/jbc.M109.058792. Epub 2009 Nov 10.

25.

A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, Burton DR, Zwick MB, Wilson IA.

J Virol. 2009 Sep;83(17):8451-62. doi: 10.1128/JVI.00685-09. Epub 2009 Jun 10.

26.

Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.

Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9057-62. doi: 10.1073/pnas.0901474106. Epub 2009 May 19.

27.

A welcome burst of human antibodies.

Zwick MB, Gach JS, Burton DR.

Nat Biotechnol. 2008 Aug;26(8):886-7. doi: 10.1038/nbt0808-886. No abstract available.

PMID:
18688242
28.

Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine.

Gach JS, Quendler H, Ferko B, Katinger H, Kunert R.

Mol Biotechnol. 2008 Jun;39(2):119-25. doi: 10.1007/s12033-008-9054-7.

PMID:
18327550
29.

Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine?

Gach JS, Quendler H, Weik R, Katinger H, Kunert R.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1405-15. doi: 10.1089/aid.2007.0089.

PMID:
18184084
30.

Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5.

Gach JS, Quendler H, Strobach S, Katinger H, Kunert R.

Mol Immunol. 2008 Feb;45(4):1027-34. Epub 2007 Sep 4.

PMID:
17804071
31.

High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris.

Gach JS, Maurer M, Hahn R, Gasser B, Mattanovich D, Katinger H, Kunert R.

J Biotechnol. 2007 Mar 10;128(4):735-46. Epub 2007 Jan 10.

PMID:
17270302
32.

Validated method for quantification of genetically modified organisms in samples of maize flour.

Kunert R, Gach JS, Vorauer-Uhl K, Engel E, Katinger H.

J Agric Food Chem. 2006 Feb 8;54(3):678-81.

PMID:
16448167

Supplemental Content

Support Center